Polarean Imaging plc announces the delivery of the latest model of Polarean’s Xenon polariser to The Department of Radiology at University of Missouri Health Care(“MUHC”).
3 October 2018 -- Polarean Imaging plc (AIM: POLX), the medical imaging technology company, with a proprietary drug device combination product for the magnetic resonance imaging(MRI) market, announces the delivery of the latest model of Polarean’s Xenon polariser to The Department of Radiology&University of Missouri Health Care(“MUHC”).
The Department of Radiology at MUHC is launching its research programme in pulmonary imaging and will use Polarean’s hyperpolarised xenon technology as part of the programme.
Richard Hullihen, CEO of Polarean, said: “We are excited to deliver the newest version of our polariser to MUHC. We are grateful to Dr Altes, MUHC, and all theskilled researchers there, for the opportunity to work together and continue our research into the clinical applications of this emerging and much needed technology.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
Enquiries:
| Polarean Imaging plc | www.polarean.com / www.polarean-ir.com | ||
| Richard Hullihen, Chief Executive Officer | Via Walbrook PR | ||
| Richard Morgan, Chairman | |||
| Northland Capital Partners Limited | Tel: +44 (0)20 3861 6625 | ||
David Hignell / Gerry Beaney / Jamie Spotswood (Corporate Finance) Rob Rees (Corporate Broking) | |||
| MC Services (European IR) | Tel: +49 (0)89 210 2280 | ||
| Raimund Gabriel | |||
| The Life Sciences Division (Financial Adviser) | |||
| Navid Malik, Director | Mob: 07957 224 730 | ||
| Alia Minhas, CEO | Mob: 07590 696 057 | ||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com | ||
Paul McManus / Anna Dunphy Helen Cresswell | Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 +44 (0)7841 917 679 | ||
